Reply to the letters to the editor 'differential influence of vemurafenib and dabrafenib on patients' lymphocytes despite similar clinical efficacy in melanoma' by diwakar et al.

Schilling B, Sondermann W, Griewank KG, Livingstone E, Zimmer L, Hillen U, Schadendorf D (2015)

Publication Type: Journal article

Publication year: 2015

Journal

Annals of Oncology Elsevier

Book Volume: 26

Pages Range: 250-251

Journal Issue: 1

DOI: 10.1093/annonc/mdu502

Involved external institutions

Universitätsklinikum Essen DE Germany (DE)

How to cite

APA:

Schilling, B., Sondermann, W., Griewank, K.G., Livingstone, E., Zimmer, L., Hillen, U., & Schadendorf, D. (2015). Reply to the letters to the editor 'differential influence of vemurafenib and dabrafenib on patients' lymphocytes despite similar clinical efficacy in melanoma' by diwakar et al. Annals of Oncology, 26(1), 250-251. https://doi.org/10.1093/annonc/mdu502

MLA:

Schilling, B., et al. "Reply to the letters to the editor 'differential influence of vemurafenib and dabrafenib on patients' lymphocytes despite similar clinical efficacy in melanoma' by diwakar et al." Annals of Oncology 26.1 (2015): 250-251.

BibTeX: Download